Nephropathic Cystinosis Treatment Market

Nephropathic Cystinosis Treatment - Global Market Outlook (2019 -2027)

4.3 (35 reviews)
Published: November 2020 ID: SMRC20100
4.3 (35 reviews)
Published: November 2020 ID: SMRC20100

This report covers the impact of COVID-19 on this global market

According to Stratistics MRC, the Global Nephropathic Cystinosis Treatment Market is accounted for $215.00 million in 2019 and is expected to reach $270.25 million by 2027 growing at a CAGR of 2.9% during the forecast period. Emergence of patient assistance, helping hand programs for nephropathic cystinosis patients and rise in awareness regarding nephropathic cystinosis among people through various programs are the major factors propelling the market growth. However, lack of healthcare professionals is hampering the market growth.


Nephropathic cystinosis is a rare form of disease. It is an inherited (autosomal recessive) lysosomal storage disorder caused by defective transport of the amino acid cystine out of lysosomes. The stored cystine is poorly soluble and crystallizes within the lysosomes of many cell types, leading to widespread tissue and organ damage. Nephropathic cystinosis treatment comprises cysteamine depletion therapy with symptomatic treatment for the disease. At a severe stage, renal transplantation option is adopted.

Based on the treatment type, the therapy segment is going to have a lucrative growth during the forecast period due to the factors such as better efficacy to cure symptoms, delayed renal transplantation, and novel therapy approaches being developed in recent times. The therapy segment is further sub-segmented into systemic depletion therapy and symptomatic therapy. Systemic depletion therapy is a more popular therapy due to being the only effective treatment option for nephropathic cystinosis.

By geography, North America is going to have a lucrative growth during the forecast period due owing to comparatively higher diagnosed patient population for nephropathic cystinosis in the region, availability of U.S. FDA approved products, and research funding for new treatment approaches. For instance, as per Cystinosis Research Network (CRN), cystinosis affects an estimated 2,000 people worldwide with just over 600 of those diagnosed living in the U.S.

Some of the key players profiled in the Nephropathic Cystinosis Treatment Market include AVROBIO, Inc, Chiesi Farmaceutici S.p.A, Eloxx Pharmaceuticals, GlaxoSmithKline plc, Horizon Therapeutics, Leadiant Biosciences, Inc, Mylan, and Recordati Rare Diseases.

Treatment Types Covered:
• Renal Transplantation
• Therapy

Applications Covered:
• Ambulatory Surgical Centres
• Clinics
• Hospitals
• Specialty/Retail Pharmacies

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019 2020, 2024, and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.


Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.